Compagnie Lombard Odier SCmA Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Compagnie Lombard Odier SCmA raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2,013.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,585 shares of the life sciences company’s stock after acquiring an additional 1,510 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Illumina were worth $207,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Trivant Custom Portfolio Group LLC grew its holdings in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares during the period. Versant Capital Management Inc grew its stake in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina in the second quarter worth $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 132 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of Illumina in the 2nd quarter valued at $61,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of ILMN opened at $145.54 on Monday. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $148.19. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The firm has a market cap of $23.18 billion, a price-to-earnings ratio of -17.86 and a beta of 1.15. The stock has a 50 day moving average of $130.19 and a 200-day moving average of $120.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the business posted $0.32 earnings per share. The firm’s revenue for the quarter was down 5.4% on a year-over-year basis. As a group, analysts forecast that Illumina, Inc. will post 3.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ILMN. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. Piper Sandler lowered their target price on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a report on Wednesday, August 28th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. Finally, Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $120.00 to $154.00 in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $150.05.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.